What is Aggrastat (tirofiban) classified as?

Aggrastat (tirofiban) is classified as an antiplatelet agent and specifically acts as a glycoprotein IIb/IIIa inhibitor. This classification is important because glycoprotein IIb/IIIa inhibitors work by blocking the final pathway for platelet aggregation, which is crucial in preventing further clot formation during acute coronary syndromes or during percutaneous coronary interventions.

As an antiplatelet medication, tirofiban is used to reduce the risk of thrombotic events by interfering with the interaction between platelets and fibrinogen, thus preventing platelet aggregation and clot formation. Understanding its mechanism helps in managing conditions related to cardiovascular health, especially in settings where rapid stabilization of a patient's condition is required. This highlights the importance of knowing the pharmacological classifications and actions of various medications in clinical practice.